Abstract Nivolumab is a standard second-line therapy for advanced esophageal squamous cell carcinoma (ESCC), based on pivotal phase III trials largely conducted in Asian populations. Real-world evidence in Western patients remains limited. Systemic inflammation- and nutrition-based indices have been proposed as prognostic biomarkers in immunotherapy but remain scarcely validated in ESCC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile